Core Viewpoint - Kingsray Biotechnology (01548) announced that its affiliate Legend Biotech Corporation will present the latest data related to CARVYKTI® and other pipelines at the 67th American Society of Hematology Annual Meeting from December 6 to 9, 2025, in San Diego [1] Group 1 - Kingsray Biotechnology's affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on November 3, 2025 [1] - The presentation at the American Society of Hematology Annual Meeting will showcase advancements related to CARVYKTI® [1]

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on November 3, 2025, and will present the latest data related to CARVYKTI® and other pipelines at the 67th American Society of Hematology Annual Meeting from December 6 to 9, 2025, in San Diego [1]. Group 1 - Kingsray Biotechnology's affiliate, Legend Biotech, is listed on the NASDAQ Global Select Market [1]. - The 67th American Society of Hematology Annual Meeting will take place in San Diego [1]. - The presentation will include the latest data on CARVYKTI® and other related pipelines [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 關於前瞻性陳述的注意事項 本公告中關於未來預期、計劃和前景的陳述，以及關於非歷史事實事項的任何其他陳述，均構 成1995年《私人證券訴訟改革法案》所指的「前瞻性陳述」。這些陳述包括但不限於：與傳奇 戰略和目標有關的表述，以及傳奇候選產品的潛在優勢。「預期」、「相信」、「繼續」、 「可能」、「估計」、「期望」、「打算」、「可以」、「計劃」、「潛在」、「預測」、 「預計」、「應該」、「目標」、「將」、「會」和類似表達旨在識別前瞻性陳述，但並非所 有前瞻性陳述都包含這些識別詞。儘管並非所有前瞻性表述都包含這些識別詞，但類似表述旨 在識別前瞻性表述。由於各種重要因素的影響，實際結果可能與這些前瞻性陳述所顯示的結果 存在實質性差異。傳奇的預期可能會受到以下因素的影響：新藥開發過程中的不確定性；意外 ...

Core Viewpoint - Kingsoft Biotech (1548.HK) has seen a significant stock price increase of 4.71% to HKD 16.67, with a year-to-date gain of nearly 70%, outperforming the market index which has risen approximately 30% during the same period [1] Group 1: Company Performance - Kingsoft Biotech's stock price has increased by 4.71% to HKD 16.67 during intraday trading [1] - The company has achieved a year-to-date stock price increase of nearly 70% [1] - The performance of Kingsoft Biotech has outpaced the Hang Seng Index, which has risen about 30% in the same timeframe [1] Group 2: Business Developments - Kingsoft Biotech announced that its affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on October 14, 2025 [1] - The report indicated that CARVYKTI® generated trade sales net revenue of approximately USD 524 million for the quarter ending September 30, 2025, under a collaboration and licensing agreement with Janssen Biotech, Inc. established on December 21, 2017 [1]

Group 1 - Kingsray Biotechnology (01548) saw a stock increase of over 3%, currently trading at 16.27 HKD with a transaction volume of 32.066 million HKD [1] - On October 14, Kingsray Biotechnology announced that, according to the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017, CARVYKTI® is expected to generate net trade sales of approximately 524 million USD for the quarter ending September 30, 2025 [1]

Core Viewpoint - Kingsray Biotechnology (01548) has seen a stock price increase of over 3%, currently trading at 16.27 HKD with a transaction volume of 32.066 million HKD, following the announcement of projected trade sales from its collaboration with Janssen Biotech, Inc. [1] Group 1 - Kingsray Biotechnology announced that CARVYKTI is expected to generate trade sales net revenue of approximately 524 million USD for the quarter ending September 30, 2025, as per the collaboration and licensing agreement established with Janssen on December 21, 2017 [1]

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its associate Legend Biotech has reported a net trade sales of approximately $524 million for CARVYKTI® for the quarter ending September 30, 2025, as per the 6-K form submitted to the SEC [1] Group 1: Company Developments - CARVYKTI® is the first CAR-T product from China approved by the FDA [1] - The product was officially approved in the U.S. in March 2022 for the treatment of relapsed or refractory multiple myeloma (R/RMM) patients [1] - CARVYKTI® has also received market approval in the European Union and Japan following its U.S. approval [1]

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI® is expected to generate trade sales net revenue of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1]. Group 1 - Kingsray Biotechnology's CARVYKTI® is projected to achieve significant sales revenue [1]. - The collaboration with Janssen Biotech, Inc. plays a crucial role in the commercialization of CARVYKTI® [1]. - The sales forecast is based on a previously established agreement from December 2017 [1].

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI® is projected to generate trade sales net revenue of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Summary by Category - **Company Performance** - CARVYKTI® is expected to achieve net trade sales of about $524 million by the end of Q3 2025 [1] - **Partnerships** - The revenue projection is based on the collaboration and licensing agreement with Janssen Biotech, Inc. signed on December 21, 2017 [1]

Core Insights - Kingsray Biotechnology (01548) announced that CARVYKTI® is expected to generate net trade sales of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Legend and Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology's CARVYKTI® is projected to achieve significant sales figures, indicating strong market potential [1] - The collaboration with Janssen Biotech, Inc. highlights strategic partnerships in the biotechnology sector [1] - The timeline for the projected sales extends to the end of Q3 2025, suggesting a long-term outlook for revenue generation [1]